首页> 美国卫生研究院文献>Genes >Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota
【2h】

Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota

机译:抑制抗生素治疗对肠道微生物的长期影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim was to describe the safety of indefinite administration of antibiotics, the so-called suppressive antibiotic therapy (SAT) and to provide insight into their impact on gut microbiota. 17 patients with SAT were recruited, providing a fecal sample. Bacterial composition was determined by 16S rDNA massive sequencing, and their viability was explored by PCR-DGGE with and without propidium monoazide. Presence of antibiotic multirresistant bacteria was explored through the culture of feces in selective media. High intra-individual variability in the genera distribution regardless of the antibiotic or antibiotic administration ingestion period, with few statistically significant differences detected by Bray-Curtis distance-based principle component analysis, permutational multivariate analysis of variance and linear discriminant analysis effect size analysis. However, the microbiota composition of patients treated with both beta-lactams and sulfonamides clustered by a heat map. Curiously, the detection of antibiotic resistant bacteria was almost anecdotic and CTX-M-15-producing E. coli were detected in two subjects. Our work demonstrates the overall clinical safety of SAT and the low rate of the selection of multidrug-resistant bacteria triggered by this therapy. We also describe the composition of intestinal microbiota under the indefinite use of antibiotics for the first time.
机译:目的是描述无限期管理抗生素的安全性,所谓的抑制抗生素治疗(坐落)并向其对肠道微生物的影响提供洞察力。 17名患有饱和患者的患者,提供粪便样品。通过16S rDNA大量测序测定细菌组合物,通过PCR-DGGE,具有和无甘料苷丙酮鉴定其活力。通过选择性培养基中的粪便培养来探讨抗生素多刺激细菌的存在。无论抗生素或抗生素给药的异常均分布,均比抗生素或抗生素给药的差异差异,均分析的统计学显着性差异,方差和线性判别分析效果尺寸分析的差异差异。然而,用热图聚集β-内酰胺和磺胺酰胺治疗的患者的微生物群组成。奇怪的是,抗生素抗性细菌的检测几乎是Anecdotic,在两个受试者中检测到产生的CTX-M-15产生的大肠杆菌。我们的作品展示了SAT的整体临床安全和通过该疗法引发的多药抗性细菌的选择的低速率。我们还在第一次描述了在无限期使用抗生素的肠道微生物群的组成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号